Cargando…
High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality
BACKGROUND: Short-acting β(2)-agonist (SABA) overuse has been associated with an increased risk of exacerbations in asthma; however, less is known about SABA use in COPD. Our aim was to describe SABA use and investigate potential associations between high SABA use and the risk of future exacerbation...
Autores principales: | Janson, Christer, Wiklund, Fredrik, Telg, Gunilla, Stratelis, Georgios, Sandelowsky, Hanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277875/ https://www.ncbi.nlm.nih.gov/pubmed/37342089 http://dx.doi.org/10.1183/23120541.00722-2022 |
Ejemplares similares
-
Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
por: Nwaru, Bright I., et al.
Publicado: (2020) -
Management and Risk of Mortality in Patients Hospitalised Due to a First Severe COPD Exacerbation
por: Janson, Christer, et al.
Publicado: (2020) -
Lack of COPD-Related Follow-Up Visits and Pharmacological Treatment in Swedish Primary and Secondary Care
por: Sandelowsky, Hanna, et al.
Publicado: (2022) -
Annual and Post-Exacerbation Follow-Up of Asthma Patients in Clinical Practice – A Large Population-Based Study in Sweden
por: Sandelowsky, Hanna, et al.
Publicado: (2022) -
Short‐acting β(2)‐agonist use and asthma exacerbations in Swedish children: A SABINA Junior study
por: Melén, Erik, et al.
Publicado: (2022)